Literature DB >> 22479045

Should erythropoiesis-stimulating agents be used in predialysis patients?

Rene Breault1.   

Abstract

Entities:  

Year:  2011        PMID： 22479045      PMCID： PMC3093423          DOI： 10.4212/cjhp.v64i2.1000

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  16 in total

1.  KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target.

Authors: 
Journal:  Am J Kidney Dis       Date:  2007-09       Impact factor: 8.860

2.  Clinical practice guidelines for evidence-based use of erythropoietic-stimulating agents.

Authors:  Louise M Moist; Rob N Foley; Brendan J Barrett; Francois Madore; Colin T White; Scott W Klarenbach; Bruce F Culleton; Marcello Tonelli; Braden J Manns
Journal:  Kidney Int Suppl       Date:  2008-08       Impact factor: 10.545

Review 3.  Diabetes, anemia and CKD: Why TREAT?

Authors:  Ajay K Singh
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

4.  Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients.

Authors:  Dennis J Cotter; Kevin Stefanik; Yi Zhang; Mae Thamer; Daniel Scharfstein; James Kaufman
Journal:  J Clin Epidemiol       Date:  2004-10       Impact factor: 6.437

5.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

6.  The prevalence of anemia in patients with chronic kidney disease.

Authors:  William McClellan; Stephen L Aronoff; W Kline Bolton; Sally Hood; Daniel L Lorber; K Linda Tang; Thomas F Tse; Brian Wasserman; Marc Leiserowitz
Journal:  Curr Med Res Opin       Date:  2004-09       Impact factor: 2.580

7.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

8.  Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Brian D Bradbury; Rachel B Fissell; Justin M Albert; Mary S Anthony; Cathy W Critchlow; Ronald L Pisoni; Friedrich K Port; Brenda W Gillespie
Journal:  Clin J Am Soc Nephrol       Date:  2006-11-29       Impact factor: 8.237

9.  Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease.

Authors:  J B Wish; G M Nassar; K Schulman; M del Aguila; R Provenzano
Journal:  Clin Nephrol       Date:  2008-04       Impact factor: 0.975

Review 10.  Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review.

Authors:  Shravanthi R Gandra; Fredric O Finkelstein; Antonia V Bennett; Eldrin F Lewis; Tracy Brazg; Mona L Martin
Journal:  Am J Kidney Dis       Date:  2009-12-23       Impact factor: 8.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.